Jiangsu Hengrui Medicine
600276.SS
#529
Rank
NZ$70.33 B
Marketcap
$11.03
Share price
0.02%
Change (1 day)
33.66%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): NZ$1.34 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$3.63 Billion. In 2023 the company made an earning of NZ$1.18 Billion, an increase over its 2022 earnings that were of NZ$1.06 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$1.34 B14.19%
2023 NZ$1.18 B11.4%
2022 NZ$1.06 B-13.65%
2021 NZ$1.22 B-34.21%
2020 NZ$1.86 B15.95%
2019 NZ$1.60 B33.03%
2018 NZ$1.21 B20.89%
2017 NZ$1.00 B23.89%
2016 NZ$0.80 B11.21%
2015 NZ$0.72 B39.5%
2014 NZ$0.52 B20.61%
2013 NZ$0.43 B11.46%
2012 NZ$0.38 B29.7%
2011 NZ$0.29 B31.16%
2010 NZ$0.22 B27.92%
2009 NZ$0.17 B5.8%
2008 NZ$0.16 B79.95%
2007 NZ$93.53 M32.89%
2006 NZ$70.38 M38.19%
2005 NZ$50.93 M21.56%
2004 NZ$41.9 M13.95%
2003 NZ$36.77 M38.06%
2002 NZ$26.63 M